FHTX Q4 2020 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$322M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$251,000

Gross Profit

-$312,000-124.3% margin

Operating Income

-$21M-8278.5% margin

Net Income

-$21M-8270.1% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

+40.2%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$18M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$256M

Total Liabilities

$109M

Stockholders' Equity

$146M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$251,000	$0	—
Gross Profit	-$312,000	$0	—
Operating Income	-$21M	-$15M	-36.8%
Net Income	-$21M	-$15M	-35.7%